127 related articles for article (PubMed ID: 38453563)
1. KMT2C and KMT2D aberrations in breast cancer.
Tinsley E; Bredin P; Toomey S; Hennessy BT; Furney SJ
Trends Cancer; 2024 Mar; ():. PubMed ID: 38453563
[TBL] [Abstract][Full Text] [Related]
2. Histone H3 lysine 4 methyltransferase KMT2D.
Froimchuk E; Jang Y; Ge K
Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
[TBL] [Abstract][Full Text] [Related]
3. COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.
Fagan RJ; Dingwall AK
Cancer Lett; 2019 Aug; 458():56-65. PubMed ID: 31128216
[TBL] [Abstract][Full Text] [Related]
4. Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma.
Dawkins JB; Wang J; Maniati E; Heward JA; Koniali L; Kocher HM; Martin SA; Chelala C; Balkwill FR; Fitzgibbon J; Grose RP
Cancer Res; 2016 Aug; 76(16):4861-71. PubMed ID: 27280393
[TBL] [Abstract][Full Text] [Related]
5. Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis.
Yang W; Ernst P
Curr Opin Hematol; 2017 Jul; 24(4):322-328. PubMed ID: 28375985
[TBL] [Abstract][Full Text] [Related]
6. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Guo C; Chen LH; Huang Y; Chang CC; Wang P; Pirozzi CJ; Qin X; Bao X; Greer PK; McLendon RE; Yan H; Keir ST; Bigner DD; He Y
Oncotarget; 2013 Nov; 4(11):2144-53. PubMed ID: 24240169
[TBL] [Abstract][Full Text] [Related]
7. The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.
Wang LH; Aberin MAE; Wu S; Wang SP
Biochem Soc Trans; 2021 Jun; 49(3):1041-1054. PubMed ID: 34156443
[TBL] [Abstract][Full Text] [Related]
8.
Rabello DDA; Ferreira VDDS; Berzoti-Coelho MG; Burin SM; Magro CL; Cacemiro MDC; Simões BP; Saldanha-Araujo F; de Castro FA; Pittella-Silva F
Cancer Cell Int; 2018; 18():26. PubMed ID: 29483845
[TBL] [Abstract][Full Text] [Related]
9. H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma.
Bosgana P; Nikou S; Dimitrakopoulos FI; Logotheti S; Tzelepi V; Kalophonos C; Bravou V; Kourea E; Sampsonas F; Zolota V
Curr Mol Pharmacol; 2021; 14(6):1028-1036. PubMed ID: 32867667
[TBL] [Abstract][Full Text] [Related]
10. KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.
Gala K; Li Q; Sinha A; Razavi P; Dorso M; Sanchez-Vega F; Chung YR; Hendrickson R; Hsieh JJ; Berger M; Schultz N; Pastore A; Abdel-Wahab O; Chandarlapaty S
Oncogene; 2018 Aug; 37(34):4692-4710. PubMed ID: 29755131
[TBL] [Abstract][Full Text] [Related]
11. Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation.
Dorighi KM; Swigut T; Henriques T; Bhanu NV; Scruggs BS; Nady N; Still CD; Garcia BA; Adelman K; Wysocka J
Mol Cell; 2017 May; 66(4):568-576.e4. PubMed ID: 28483418
[TBL] [Abstract][Full Text] [Related]
12. Lpt, trr, and Hcf regulate histone mono- and dimethylation that are essential for Drosophila heart development.
Huang W; Zhu JY; Fu Y; van de Leemput J; Han Z
Dev Biol; 2022 Oct; 490():53-65. PubMed ID: 35853502
[TBL] [Abstract][Full Text] [Related]
13. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.
Liu L; Kimball S; Liu H; Holowatyj A; Yang ZQ
Oncotarget; 2015 Feb; 6(4):2466-82. PubMed ID: 25537518
[TBL] [Abstract][Full Text] [Related]
15. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
16. Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Chang A; Liu L; Ashby JM; Wu D; Chen Y; O'Neill SS; Huang S; Wang J; Wang G; Cheng D; Tan X; Petty WJ; Pasche BC; Xiang R; Zhang W; Sun P
Cancer Res; 2021 Jun; 81(12):3358-3373. PubMed ID: 33853832
[TBL] [Abstract][Full Text] [Related]
17. The cancer COMPASS: navigating the functions of MLL complexes in cancer.
Ford DJ; Dingwall AK
Cancer Genet; 2015 May; 208(5):178-91. PubMed ID: 25794446
[TBL] [Abstract][Full Text] [Related]
18. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition.
Wang C; Lee JE; Lai B; Macfarlan TS; Xu S; Zhuang L; Liu C; Peng W; Ge K
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11871-11876. PubMed ID: 27698142
[TBL] [Abstract][Full Text] [Related]
19. Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.
Larsson C; Cordeddu L; Siggens L; Pandzic T; Kundu S; He L; Ali MA; Pristovšek N; Hartman K; Ekwall K; Sjöblom T
Clin Epigenetics; 2020 May; 12(1):74. PubMed ID: 32471474
[TBL] [Abstract][Full Text] [Related]
20. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
Limberger T; Schlederer M; Trachtová K; Garces de Los Fayos Alonso I; Yang J; Högler S; Sternberg C; Bystry V; Oppelt J; Tichý B; Schmeidl M; Kodajova P; Jäger A; Neubauer HA; Oberhuber M; Schmalzbauer BS; Pospisilova S; Dolznig H; Wadsak W; Culig Z; Turner SD; Egger G; Lagger S; Kenner L
Mol Cancer; 2022 Mar; 21(1):89. PubMed ID: 35354467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
